In a pilot clinical trial in AD patients, high-dose resveratrol was found to penetrate the blood–brain barrier and modulate AD biomarkers (such as Aβ40 levels and inflammatory markers), supporting the idea that SIRT1 activation is achievable in humans (Turner et al., 2015). This evidence concerns the gene SIRT1 and Alzheimer disease.